Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second malignant neoplasms associated with immunosuppressive medications

I Penn

    Cancer
    |February 1, 1976
    PubMed
    Summary

    Immunosuppressive therapy increases cancer risk in organ transplant recipients and those with prior cancers. However, chemotherapy

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Depressed immunity and skin cancer.

    Immunology today·2014
    Same author

    Immunosuppression and Neoplasia.

    Behring Institute Mitteilungen·2010
    Same author

    Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting.

    International journal of cardiovascular interventions·2003
    Same author

    Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina.

    Circulation·2002
    Same author

    Some problems with posttransplant lymphoproliferative disease.

    Transplantation·2001
    Same author

    HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients.

    Gynecologic oncology·2000

    Area of Science:

    • Oncology
    • Immunology
    • Transplantation

    Background:

    • Immunosuppressive therapy is crucial for organ transplant recipients.
    • This therapy is associated with an increased risk of de novo cancers.
    • The risk extends to patients with pre-existing malignancies.

    Purpose of the Study:

    • To evaluate the incidence of new tumors in organ homograft recipients with pre-existing cancers.
    • To assess the development of new malignancies in patients treated with cancer chemotherapeutic agents.

    Main Methods:

    • Retrospective analysis of 101 organ homograft recipients with prior cancers.
    • Analysis of 160 patients treated for 161 neoplasms, focusing on immunosuppressive chemotherapy effects.

    Main Results:

    • A 4% incidence of new tumors was observed in organ homograft recipients with pre-existing cancers.
    • 166 new malignancies developed in 160 patients receiving chemotherapy for neoplasms.
    • The immunosuppressive effects of chemotherapy are implicated in new cancer development.

    Conclusions:

    • Immunosuppression in organ transplantation is linked to de novo cancer development.
    • Chemotherapy-induced immunosuppression may lead to secondary malignancies.
    • The benefits of chemotherapy for primary neoplasms outweigh the risk of new cancers in advanced cases.

    Related Experiment Videos